InvestorsHub Logo
Followers 40
Posts 3318
Boards Moderated 0
Alias Born 08/18/2009

Re: None

Tuesday, 05/07/2019 8:32:32 AM

Tuesday, May 07, 2019 8:32:32 AM

Post# of 3845
Key Highlights and Upcoming Milestones:

NDA submitted to the FDA for Talicia® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA approval

FDA meeting planned for H2/2019 to discuss design of confirmatory Phase 3 study and path to potential approval for RHB-104 for Crohn’s disease

Initiation of pivotal Phase 3 study expected in H2/2019 with RHB-204 for first-line treatment of pulmonary nontuberculous mycobacteria (NTM) infections

Net revenues of $1.7 million, an increase of 28% over previous quarter

Debt-free balance sheet with $45.5 million in cash as of March 31, 2019, with quarterly cash burn at its lowest in two years
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News